Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium plus riluzole versus placebo plus riluzole in amyotrophic lateral sclerosis
2007-002379-16Phase 4Terminated
- Sponsor
- Neuromed
- Start
- Nov 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-blind trial of lithium in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Neuromed. Primary endpoints: Evaluation of survival without complications and Evaluation of survival with complications. Started Nov 2007; status: terminated.
02
Drugs
lithium
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2007-002379-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002379-16.